Loading
OS-151 is an experimental modified BCG from OncoSTING for bladder cancer, built to release an immune-activating molecule. It is in laboratory testing.
OS-151 is the lead product of OncoSTING, a second-generation BCG for non-muscle invasive bladder cancer that produces a STING agonist; the NIH RePORTER abstract describes the strain as overexpressing c-di-AMP. OncoSTING also plans intratumoral use in other solid tumours. Evidence is preclinical.
A recombinant Bacillus Calmette-Guerin strain that overexpresses c-di-AMP, a STING agonist, to add STING-driven innate immune activation to BCG's effect, as the developer's award abstract describes.
1.OS-151 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"OS-151" OR ABSTRACT:"OS-151" OR TITLE:"rBCG-STING" OR ABSTRACT:"rBCG-STING") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OS-151, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/